Last reviewed · How we verify
EGFR mutation-positive, unresectable or recurrent non-small cell lung cancer
Approved treatments
- dacomitinib hydrate · Pfizer Inc.
The usual adult starting dosage for oral use is 45mg of dacomitinib hydrate once daily. The dose sho - Vizimpro · Pfizer Inc.
Irreversible pan-HER kinase inhibitor targeting EGFR, HER2, HER4, and EGFR-activating mutations. - Vizimpro · Pfizer
Vizimpro works by blocking the EGFR tyrosine kinase, a protein that helps cancer cells grow and survive.
Clinical guidelines
- FDA label — 1L
VIZIMPRO is indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21 L858R substitution mutations as detected by an FDA-approved test. - FDA label — 1L
VIZIMPRO is indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21 L858R substitution mutations as detected by an FDA-approved test.
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- EGFR mutation-positive, unresectable or recurrent non-small cell lung cancer patent landscape — cliff calendar, originator estates, attackable patents
- EGFR mutation-positive, unresectable or recurrent non-small cell lung cancer treatment landscape brief
- EGFR mutation-positive, unresectable or recurrent non-small cell lung cancer treatment updates RSS
Frequently asked questions about EGFR mutation-positive, unresectable or recurrent non-small cell lung cancer
What drugs treat EGFR mutation-positive, unresectable or recurrent non-small cell lung cancer?
Tracked treatments include dacomitinib hydrate, Vizimpro.
What is the treatment for EGFR mutation-positive, unresectable or recurrent non-small cell lung cancer?
Standard treatment for EGFR mutation-positive, unresectable or recurrent non-small cell lung cancer includes dacomitinib hydrate, Vizimpro. See the treatment landscape page for first-line, second-line and salvage options.
What are the treatment guidelines for EGFR mutation-positive, unresectable or recurrent non-small cell lung cancer?
FDA label publishes guidelines for EGFR mutation-positive, unresectable or recurrent non-small cell lung cancer. 2 guideline references tracked.
Related
- Treatment landscape: EGFR mutation-positive, unresectable or recurrent non-small cell lung cancer patent cliff · EGFR mutation-positive, unresectable or recurrent non-small cell lung cancer CI report
- Treatment: dacomitinib hydrate · Pfizer Inc.
- Treatment: Vizimpro · Pfizer Inc.
- Treatment: Vizimpro · Pfizer
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing